People In Brief: Pfizer, Valeant, Vitalah, Aker, Mulberry Love
This article was originally published in The Tan Sheet
Executive Summary
Schulman out, Bourla in at Pfizer; Valeant appoints Kellen chairman; Vitalah VP leads Oxylent sales; Aker names Australia head; CRN builds regulatory team; more People In Brief.
You may also be interested in...
Health And Wellness Executive Decisions: CHPA Counsel, CRN SVP, Gellar For Colgate
CHPA appoints Anne Marie Murphy deputy general counsel; CRN promotes Andrew Wong to senior VP, scientific and regulatory affairs; and Sarah Michelle Gellar promotes the Colgate Optic White High Impact line.
Pfizer Reorganizes Internally, Closer To Decision On Splitting Business
Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.